GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli ...

Eli Lilly will take the baton on developing a peripheral pain candidate from Confo Therapeutics, handing off $40 million upfront and a potential $590 million total down the track if all goes well.

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with ...

The pain drug market has many products, but there’s still a need for pills with better properties, such as avoiding addiction. Eli Lilly sees potential in the non-opioid pain drug research from Confo ...

Confo Therapeutics’ business development team is on a roll. Weeks after licensing its lead candidate to Eli Lilly, the Belgian biotech has landed a 168 million euro ($182 million) deal with Daiichi ...

Ghent, Belgium – October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million ...

Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus ...

Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has dipped another toe into the water with a small licensing deal with Belgian start-up, Confo ...

Eli Lilly and Company and Confo Therapeutics, a developer of drugs that target G-protein-coupled receptors (GCPRs), have signed a worldwide licensing agreement for Confo compound CFTX-1554 and back-up ...

Eli Lilly and company (Lilly) has signed a licensing agreement with Confo Therapeutics (Confo) for the Belgium biotech’s neuropathic pain candidate CFTX-1554, as well as back-up compounds. Currently ...

Eli Lilly reached a deal with Confo Therapeutics to gain licensing to Confo’s non-opioid neuropathic pain candidate, CFTX-1554, the companies announced Thursday. In the deal, Confo will receive $630 ...